Received Apr 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
No additional AE; I received my first dose. Unfortunately, I was unable to receive the second dose within the recommended time frame and instead received it approximately one year later, in 2025. I have not yet received the third dose.; This spontaneous report was received from a patient unknown age and gender concerning on her/himself via company representative. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On an unknown date in October 2024, the patient was vaccinated with the first dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection, 1 dosage form, total, (Batch/Lot Number and expiration date was not provided) as prophylaxis. On an unknown date in 2025 (reported as "approximately one year later"), the patient was vaccinated with the second dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection, 1 dosage form, total, (Batch/Lot Number and expiration date was not provided) as prophylaxis (Inappropriate schedule of product administration). The patient has not yet received the third dose. No adverse event was reported. Lot # is being requested and will be submitted if received